Completed
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
J1I-MC-GZBB - ClinicalTrials.gov - NCT04143802
The main purpose of this study is to learn about the side effects of LY3437943 when given to participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943, dulaglutide, or placebo given just under the skin.
How long will I be in the trial?
The study will last up to about 5 months and will include 16 visits to the study center.
Completed
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
J1I-MC-GZBB - ClinicalTrials.gov - NCT04143802
The main purpose of this study is to learn about the side effects of LY3437943 when given to participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943, dulaglutide, or placebo given just under the skin.
How long will I be in the trial?
The study will last up to about 5 months and will include 16 visits to the study center.
Key Requirements
Age :
20-70
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
20-70
Sex
All
Participants must
Participants must be diagnosed with type 2 diabetes for at least six months
Participants must have stable body weight for the last 3 months
Participants must be overweight or very overweight - Male participants must agree to use birth control during the study and for 90 days afterward and female participants must not be able to get pregnant
Participants must NOT
Participants must not have known complication of diabetes
Participants must not have Type 1 diabetes mellitus
Participants must not have uncontrolled diabetes, (meaning that they required hospitalization for treatment of life-threatening complications of diabetes in the last six months)
Participants must not have had severe low blood sugar requiring emergency treatment
Participants must not have inflammation of the pancreas
Participants must not have known liver disease
Trial Summary
Conditions the trial is for
Adult Type 2 Diabetes
What the trial is testing?
LY3437943, Dulaglutide, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
75
Trial Dates
December 2019 - December 2020
Trial Phase
1
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
20-70
Sex
All
Participants must
Participants must be diagnosed with type 2 diabetes for at least six months
Participants must have stable body weight for the last 3 months
Participants must be overweight or very overweight - Male participants must agree to use birth control during the study and for 90 days afterward and female participants must not be able to get pregnant
Participants must NOT
Participants must not have known complication of diabetes
Participants must not have Type 1 diabetes mellitus
Participants must not have uncontrolled diabetes, (meaning that they required hospitalization for treatment of life-threatening complications of diabetes in the last six months)
Participants must not have had severe low blood sugar requiring emergency treatment
Participants must not have inflammation of the pancreas
Participants must not have known liver disease
Trial Summary
Conditions the trial is for
Adult Type 2 Diabetes
What the trial is testing?
LY3437943, Dulaglutide, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
75
Trial Dates
December 2019 - December 2020
Trial Phase
1
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Adult Type 2 Diabetes Resources
